deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03428217

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma (CANTATA)

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)

Sponsor: Calithera Biosciences, Inc

Conditions Advanced Renal Cell Carcinoma Metastatic Renal Cell Carcinoma
Interventions CB-839 Cabozantinib Placebo
Updated 24 times since 2018 Last updated: Feb 21, 2023 Started: Apr 24, 2018 Primary completion: Aug 31, 2020 Completion: Jul 16, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Advanced Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma and is currently completed. Calithera Biosciences, Inc leads this study, which shows 24 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Apr 2019 · 3 months · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Jan 2021 · 14 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Apr 2023 · 12 months · monthly snapshot~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

24 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Apr 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Apr 2022 — Apr 2023 [monthly]

    Completed PHASE2

▶ Show 19 earlier versions

  1. Sep 2021 — Apr 2022 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Nov 2019 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  5. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  6. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  7. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  8. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  9. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE2

  10. Jan 2019 — Apr 2019 [monthly]

    Recruiting PHASE2

  11. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE2

  12. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  13. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  14. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  15. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  16. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  17. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  18. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  19. Mar 2018 — May 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Calithera Biosciences, Inc
Data source: Calithera Biosciences, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Auckland, New Zealand , Augusta, United States , Ballarat, Australia , Baltimore, United States , Barcelona, Spain , Benowa, Australia , Berlin, Germany , Besançon, France , Birmingham, United States and 106 more locations